Cite
HARVARD Citation
Geller, M. et al. (2014). SAT0479 Early Findings from Prolia® Post-Marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis. Annals of the rheumatic diseases. pp. 766-767. [Online].